Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by MONECO Advisors LLC

MONECO Advisors LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 8.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 482 shares of the medical research company’s stock after selling 46 shares during the period. MONECO Advisors LLC’s holdings in Thermo Fisher Scientific were worth $285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in TMO. Mystic Asset Management Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $29,000. Lee Financial Co acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $32,000. Sumitomo Mitsui Financial Group Inc. raised its position in Thermo Fisher Scientific by 141.7% during the fourth quarter. Sumitomo Mitsui Financial Group Inc. now owns 58 shares of the medical research company’s stock worth $38,000 after acquiring an additional 34 shares during the period. Lloyd Advisory Services LLC. raised its position in Thermo Fisher Scientific by 294.1% during the first quarter. Lloyd Advisory Services LLC. now owns 67 shares of the medical research company’s stock worth $40,000 after acquiring an additional 50 shares during the period. Finally, Tyler Stone Wealth Management acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $47,000. 87.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TMO. Wells Fargo & Company cut shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and reduced their price objective for the stock from $605.00 to $525.00 in a research report on Monday, April 25th. Barclays upped their target price on shares of Thermo Fisher Scientific from $630.00 to $685.00 and gave the stock an “overweight” rating in a report on Monday, August 1st. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $670.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, July 29th. Finally, SVB Leerink upped their target price on shares of Thermo Fisher Scientific from $630.00 to $650.00 and gave the stock an “outperform” rating in a report on Friday, July 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $661.08.

Insiders Place Their Bets

In other news, COO Michel Lagarde sold 17,150 shares of the stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $548.30, for a total transaction of $9,403,345.00. Following the sale, the chief operating officer now owns 15,758 shares of the company’s stock, valued at $8,640,111.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $588.36, for a total transaction of $5,883,600.00. Following the sale, the chief executive officer now owns 183,373 shares of the company’s stock, valued at $107,889,338.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michel Lagarde sold 17,150 shares of the stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $548.30, for a total transaction of $9,403,345.00. Following the sale, the chief operating officer now directly owns 15,758 shares in the company, valued at approximately $8,640,111.40. The disclosure for this sale can be found here. Insiders sold a total of 50,994 shares of company stock valued at $29,033,170 over the last 90 days. 0.43% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Up 0.0 %

Shares of TMO opened at $590.26 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $231.06 billion, a P/E ratio of 31.41, a P/E/G ratio of 1.84 and a beta of 0.83. The firm has a 50-day moving average price of $549.03 and a 200 day moving average price of $557.79. Thermo Fisher Scientific Inc. has a 12-month low of $497.83 and a 12-month high of $672.34.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last announced its earnings results on Thursday, July 28th. The medical research company reported $5.51 earnings per share for the quarter, topping the consensus estimate of $4.92 by $0.59. The company had revenue of $10.97 billion during the quarter, compared to analyst estimates of $9.95 billion. Thermo Fisher Scientific had a net margin of 17.37% and a return on equity of 24.36%. Thermo Fisher Scientific’s revenue was up 18.3% compared to the same quarter last year. During the same quarter last year, the firm posted $5.60 earnings per share. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 22.92 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 14th. Shareholders of record on Thursday, September 15th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 0.20%. The ex-dividend date is Wednesday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.39%.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.